Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

被引：19
|
作者：
Han, Chanhee [1 ]
Bellone, Stefania [1 ]
Zammataro, Luca [1 ]
Schwartz, Peter E. [1 ]
Santin, Alessandro D. [1 ]
机构：
[1] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2018年 / 25卷
关键词：
Binimetinib; MEK162; Low-grade ovarian cancer; Serous; Recurrent; Treatment-resistant;
D O I：
10.1016/j.gore.2018.05.011
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Background: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC. CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation experienced a dramatic clinical response to Binimetinib (MEK162), a mitogen-activated protein kinase (MEK) inhibitor, after failing multiple chemotherapy and hormonal treatments. An 81% reduction of target lesions by RECIST 1.1 over 31 months of response duration was confirmed with serial CT scans. Episodes of drug-related toxicity (pneumonitis) easily resolved without sequelae with the use of oral steroids. Conclusion: Binimetinib may present a new treatment option for hormone-and chemotherapy-resistant LGSOC harboring KRAS mutations.
引用
收藏
页码：41 / 44
页数：4
相关论文
共 50 条
  • [21] Low-Grade Serous Ovarian Cancer: a Unique Disease
    Schmeler, Kathleen M.
    Gershenson, David M.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (06) : 519 - 523
  • [22] Low-grade serous ovarian cancer: State of the science
    Slomovitz, Brian
    Gourley, Charlie
    Carey, Mark S.
    Malpica, Anais
    Shih, Ie-Ming
    Huntsman, David
    Fader, Amanda N.
    Grisham, Rachel N.
    Schlumbrecht, Matthew
    Sun, Charlotte C.
    Ludemann, Jane
    Cooney, Gail Austin
    Coleman, Robert
    Sood, Anil K.
    Mandi, Haider
    Wong, Kwong K.
    Covens, Allan
    O'Malley, David M.
    Lecuru, Fabrice
    Cobb, Lauren P.
    Caputo, Thomas A.
    May, Taymaa
    Huang, Marilyn
    Siemon, John
    Fernandez, Marta Llaurado
    Ray-Coquard, Isabelle
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (03) : 715 - 725
  • [23] Novel therapeutics in low-grade serous ovarian cancer
    Cobb, Lauren
    Gershenson, David
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (03) : 377 - 384
  • [24] Epidemiology of low-grade serous ovarian cancer - Discussion
    Greer, Benjamin E.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 198 (04)
  • [25] Low-grade serous ovarian cancer: a unique disease
    Kathleen M. Schmeler
    David M. Gershenson
    Current Oncology Reports, 2008, 10 : 519 - 523
  • [26] A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS/RAF PATHWAY-ACTIVATED TUMORS
    Robison, Nathan
    Pauly, Jasmine
    Malvar, Jemily
    Gruber-Filbin, Mariella
    de Mola, Rebecca Loret
    Dorris, Kathleen
    Bendel, Anne
    Bowers, Daniel
    Bornhorst, Miriam
    Gauvain, Karen
    Leary, Sarah
    Diaz, Patricia
    Tan, Yi Juin
    Margol, Ashley
    Dhall, Girish
    Rosser, Tena
    Bandopadhayay, Pratiti
    Davidson, Tom
    Ullrich, Nicole
    Borchert, Mark
    Nelson, Marvin
    Sinai, Claire
    Ligon, Keith
    Sposto, Richard
    Kieran, Mark
    NEURO-ONCOLOGY, 2018, 20 : 114 - 114
  • [27] Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer
    Bussies, Parker L.
    Schlumbrecht, Matthew
    ONCOLOGIST, 2020, 25 (07): : E1124 - E1126
  • [28] Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States
    Silberman, Jason
    Bercow, Alexandra
    Gockley, Allison Ann
    Eisenhauer, Eric L.
    Sisodia, Rachel
    Randall, Thomas Christopher
    Melamed, Alexander
    Bregar, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States
    Silberman, Jason N.
    Bercow, Alexandra S.
    Gockley, Allison A.
    Eisenhauer, Eric L.
    Sisodia, Rachel
    Randall, Thomas
    del Carmen, Marcela G.
    Goodman, Annekathryn
    Castro, Cesar M.
    Melamed, Alexander
    Bregar, Amy J.
    GYNECOLOGIC ONCOLOGY, 2023, 175 : 60 - 65
  • [30] A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
    Cho, May Thet
    Lim, Dean
    Synold, Timothy W.
    Frankel, Paul Henry
    Leong, Lucille A.
    Chao, Joseph
    Chung, Vincent M.
    Chen, Yuan
    Sentovich, Stephen
    Luevanos, Eloise
    Fakih, Marwan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345